_ Our products Pharmaceutical products Livazo Ophthalmology products Avansee Diagnostic products Livazo Livazo®/Livalo® pitavastatin is a fully synthetic and highly potent statin available across Asia, Europe, Latin America and North America. It is indicated for the reduction of elevated total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in adult patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia, and combined (mixed) dyslipidemia, when response to dietary and other non-pharmacological measures are inadequate. Since its 2003 launch in Japan, pitavastatin has accumulated millions of patient-years of exposure and has confirmed its place in the statin armamentarium, particularly for patients who require high-density lipoprotein cholesterol (HDL-C) raising or where poly-pharmacy exists, with a risk of drug-to-drug interactions. More recently, a study conducted in Japan demonstrated that pitavastatin did not increase the risk of developing diabetes in a large group of patients with impaired glucose tolerance. Pitavastatin is marketed in several European countries by our partner Recordati (primarily under the Livazo® brand name). For MENA it is marketed and distributed by Algorithm S.A.L. For more information on ordering pitavastatin or for patient materials, please get in touch with our partners. Algorithm SAL https://www.algorithm-lb.com/home Tel:+961 9 222 050 Recordati S.p.A https://www.recordati.com/en/ +39 800 167 999 Work with us For more information on our partnership opportunities please get in touch Downloads Pitavastatin Fact Sheet Cholesterol Fact Sheet Glossary of Terms SmPC Kowa Pharmaceutical Europe Co. Ltd. 105 Wharfedale Road Winnersh Triangle Wokingham Berkshire, RG41 5RB CONTACT US Our products Livazo Avansee Research & development Pipeline Pemafibrate K-877 Ripasudil K-321 Adverse event reporting Kowa routinely monitors the safety of all its medicines. This includes review of safety data from clinical studies, and collection of reports and cases of adverse events for marketed products. REPORT ADVERSE EVENT Copyrights © 2020 Kowa Pharmaceutical Europe Co. Ltd. All rights reserved. Date of preparation: 11 / 2020 UIN: KPE20 00002 Privacy policy Cookie policy Terms of use